Holen Sie sich die Stockscreener-App
19.38
6.15%
-1.27
Handel nachbörslich:
19.50
0.12
+0.62%
Schlusskurs vom Vortag:
$20.65
Offen:
$20.6
24-Stunden-Volumen:
1.80M
Relative Volume:
1.02
Marktkapitalisierung:
$3.07B
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-512.54M
KGV:
-6.5272
EPS:
-2.9691
Netto-Cashflow:
$-422.10M
1W Leistung:
+7.19%
1M Leistung:
-1.57%
6M Leistung:
+27.33%
1J Leistung:
+64.52%
1-Tages-Spanne:
$19.22
$20.80
1-Wochen-Bereich:
$18.74
$20.80
52-Wochen-Spanne:
$10.57
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
19.38 | 3.27B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-01-03 | Eingeleitet | William Blair | Outperform |
| 2024-12-16 | Hochstufung | Stifel | Hold → Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
| 2023-01-30 | Eingeleitet | SVB Securities | Outperform |
| 2022-12-05 | Eingeleitet | Cowen | Outperform |
| 2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-02 | Eingeleitet | BofA Securities | Buy |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-05-18 | Eingeleitet | UBS | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
| 2020-02-19 | Eingeleitet | Stifel | Hold |
| 2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-26 | Eingeleitet | Wedbush | Neutral |
| 2019-09-13 | Eingeleitet | Nomura | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Eingeleitet | Janney | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Eingeleitet | Goldman | Neutral |
| 2018-01-02 | Eingeleitet | JP Morgan | Overweight |
| 2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Takeda Exits Dementia Drug Partnership With Denali TherapeuticsHere's Why - Benzinga
Takeda Breaks Up With Denali, Dumps Dementia Drug - BioSpace
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Regains Full Control Of DNL593 As It Advances Toward Key 2026 Readout - RTTNews
Takeda (TAK) Ends Collaboration on Drug Development with Denali Therapeutics - gurufocus.com
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Stake Increased by Aberdeen Group plc - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNLI Technical Analysis & Stock Price Forecast - Intellectia AI
Denali Reclaims DNL593 Rights Concentrating Dementia Drug Risks And Upside - Sahm
Denali Therapeutics Inc. (DNLI) stock price, news, quote and history - Yahoo Finance Singapore
Denali Regains DNL593 Rights After Takeda Collaboration Ends - TipRanks
Denali Therapeutics Regains Full Rights to DNL593 as Takeda Ends 2018 Collaboration - TradingView
Denali Therapeutics Inc. And Takeda Terminate Collaboration Agreement For DNL593 - marketscreener.com
Takeda exits DNL593 deal; Denali (NASDAQ: DNLI) takes full control of FTD-GRN drug - Stock Titan
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - The Manila Times
Takeda exits dementia drug pact, Denali targets trial data by 2026 end - Stock Titan
Aug Opening: Is Denali Therapeutics Inc a turnaround storyQuarterly Market Review & Community Verified Trade Alerts - baoquankhu1.vn
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Market Overview: Will Denali Therapeutics Inc outperform small cap indexesQuarterly Market Review & Weekly High Return Opportunities - baoquankhu1.vn
Pullback Watch: Will Denali Therapeutics Inc benefit from government policy2026 AllTime Highs & Capital Protection Trade Alerts - baoquankhu1.vn
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - minichart.com.sg
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
Denali Therapeutics Secures $200 Million Royalty Funding - TipRanks
Denali Therapeutics receives $200 million from royalty agreement after FDA approval - Investing.com India
Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK - Stock Titan
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA NodWhat's Changed - Yahoo Finance
Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition? - simplywall.st
(DNLI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter SyndromeSlideshow (NASDAQ:DNLI) 2026-03-27 - Seeking Alpha
Denali Therapeutics (DNLI): Goldman Sachs Raises Price Target to $40 | DNLI Stock News - GuruFocus
Stifel Nicolaus Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00 at HC Wainwright - Defense World
(DNLI.O) | Stock Price & Latest News - Reuters
FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs - MedCity News
Vanguard disaggregation: no beneficial DNLI shares reported (DNLI) - Stock Titan
Denali Receives FDA Approval for Hunter Syndrome Treatment, Shares Rise - Bitget
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up - Yahoo Finance
Morgan Stanley Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.7%Time to Sell? - MarketBeat
H.C. Wainwright raises Denali Therapeutics price target to $42 By Investing.com - Investing.com Australia
The Goldman Sachs Group Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
H.C. Wainwright raises Denali Therapeutics price target to $42 - Investing.com UK
Denali Therapeutics (DNLI) Receives Analyst Rating Update from B - gurufocus.com
Robert W. Baird Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Benzinga
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):